Tech Company Financing Transactions
Azafaros Funding Round
On 5/13/2025, Azafaros raised $148 million in Series B funding from Forbion Growth Opportunities Fund II, Jeito Capital and BioGeneration Ventures.
Transaction Overview
Company Name
Announced On
5/13/2025
Transaction Type
Venture Equity
Amount
$148,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to accelerate the development of its lead product, nizubaglustat, scheduled to enter Phase 3 studies for Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses later this year.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Gooimeer 2-35
Naarden, 1411 DC
The Netherlands
Naarden, 1411 DC
The Netherlands
Phone
Undisclosed
Website
Email Address
Overview
Founded in 2018, Azafaros has leveraged on decades of discovery by professors Hans Aerts, Hermen Overkleeft, and Stan van Boeckel at Leiden University and the Academic Medical Center in the Netherlands. Expanding on their research and led by highly experienced industry experts in rare diseases, Azafaros is working on building a pipeline of disease-modifying therapeutics to offer new treatment options to patients and their families.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 5/13/2025: Lignin Industries venture capital transaction
Next: 5/13/2025: Usul venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We document every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs